GRIFOLS PLASMA: genotype 2 vB19 sample

Slides:



Advertisements
Similar presentations
Marta José, Instituto Grifols S.A., Barcelona, SPAIN
Advertisements

Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.
Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:
Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA
Full characterization of HAV RNA window period positive blood donations in Germany SoGAT XVIII Bethesda.
SOGAT Validation of HCV-RNA detection in small test pools on cadaveric samples Marco Koppelman #, Theo Cuypers #, Mirjam de Waal #, Maarten.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
Standardization – CBER update June 12, 2007 XX SoGAT Indira Hewlett, Ph.D. Chief, Lab. of Molecular Virology DETTD/CBER/FDA.
Persistent human erythrovirus infection in blood donors National Blood Service, UK Div. Transfusion Medicine, University of Cambridge, UK Public Health.
Commercial Assays and Detection of Parvovirus B19 genotypes Dr Sally A. Baylis, Division of Virology NIBSC.
Parvovirus B19 Genotype 2 Plasma, Sourced from the US Dr Sally A. Baylis, Division of Virology NIBSC.
Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.
Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.
NAT Detection of Blood Borne Viral Markers in Tissues from Cadaver Donors John Saldanha 1 and David Padley 2 1 Canadian Blood Services, Ottawa, Canada.
Phylogenetic analysis of genotype 3 parvovirus B19 in Ghana, West Africa.
Active B19 virions production in hepatoblastoma and hepatocarcinoma cell lines: amplification and genomic stability. Op de beeck A. 1, Draps M.-L. 1, Baurin.
Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.
Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.
Performance of Chiron Quantitative and Qualitative HBV PCR Assay and Confirmation of HBV Yield Cases Yiu-Lian Fong, Ph.D, Associate Director June 13, 2007.
Natural history of HBV infection (adapted from Torbenson Lancet 2003) Chronic infection Healthy carriage Recovery occult DNA Anti-HBe Anti-HBc Immune response.
NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.
SoGAT 2005 Donor screening for parvovirus B19 antibodies: Reducing or eliminating the risk of transmission SoGAT 2005 Gordon Elliott Biotrin 93 The Rise.
Elisa Moretti Process and Analytical Development KEDRION S.p.A SoGAT XVI Paul Ehrlich Institut - Langen, Germany 3 rd July 2003 Automated Extraction for.
Maternofetal transmission of human parvovirus B19 genotype 3 in Ghana, West Africa D Candotti, K Danso, A Parsyan, A Dompreh, J- P Allain National Blood.
Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVII, Paris, Paris 2004 B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion.
An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.
Novel and Related Variant Parvoviruses in Human Plasma Jacqueline Fryer and Sally Baylis National Institute for Biological Standards and Control Eric Delwart.
Confidential Extending the Armored RNA Technology to DNA Cindy WalkerPeach, Ph.D. Director, Development and Operations Ambion Diagnostics BSI EN ISO9001:2000.
Detection of Parvovirus B19 Variants in Factor VIII Concentrates Mei-ying W. Yu 1, Yansheng Geng 1, Susan Wong 2, Kevin Brown 3 ; 1 CBER/FDA, U.S.A.; 2.
Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVI, Langen 3 rd July 2003 Immediate Parvo B19 NAT testing of pooled donor samples: logistics and.
SOGAT Presence (absence) of genotype 2 and 3 Erythrovirus DNA in manufacturing plasma Theo Cuypers, Marco Koppelman, Margret Sjerps, Henk Reesink.
Sean Doyle National University of Ireland, Maynooth, Ireland. Parvovirus B19 Infection in Seronegative and Seropositive Individuals – Implications for.
A logcopies/ml b IU/ml HBV DNA levels ALT levels Figure S1.
Saeko Mizusawa, Yoshiaki Okada
In The Name of God.
Ann Intern Med. 2017;167(1):1-7. doi: /M Figure Legend:
Human Parvovirus PARV4 in Blood and Plasma Products
Use of next generation Sequencing (NGS) at a National Reference Laboratory, Denmark 2015/16 Authors: Thea Kølsen Fischer, Ramona Trebbien, Jannik Fonager,
Testing for Parvovirus B19 - Broadening the Assay to Cover Variants
Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology
Supplemental Figure 2. (A) AtplaIVA-1 and AtplaIVA-2 null transcription lines for AtPLAIVA mRNA. RNAs from the relevant wild type Col were isolated.
Results of Recent EQA Panels for Blood Borne Viruses
Table 1. Laboratory Data on Admission
Factor xiiia enzyme Human Factor XIII is cleaved with human alpha thrombin. The thrombin is subsequently removed via chromatography. The above protein.
Characterisation of HBV DNA in reference preparations
Lamivudine + INF - a At each visit: clinical examination, transaminase
توکسوپلاسماگوندای توکسوپلاسموز بیماری می باشد که توسط انگل اجباری داخل سلولی تحت عنوان توکسوپلاسما گوندای از رده کوکسیدیا ایجاد می شود. این انگل دارای.
Performance Characteristics of a Quantitative Hepatitis C Virus RNA Assay Using COBAS AmpliPrep Total Nucleic Acid Isolation and COBAS TaqMan Hepatitis.
A Novel ABO Gene Variant Leads to Discrepant Results in Forward/Reverse and Molecular Blood Grouping Transfus Med Hemother 2013;40:
Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test Lutz Pichl, Volkmar Schottstedt German Red Cross Blood Transfusion.
Evaluation of Candidate Standard XX (97/650)
K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003
Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K
Viral Safety of Blood Products in Taiwan
Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of.
Investigation of human parvovirus B19 occurrence and genetic variability in different leukaemia entities  A.C. da Costa, I. Bendit, A.C.S. de Oliveira,
1st International Standard for HIV-1 RNA NIBSC Code 97/656
Distributions of parvovirus B19 genotype 1-3 in blood donations
به نام خداوند بخشنده مهربان
Comparison of a commercial and ‘in house’ assay for B19 DNA
Phylogenetic analysis of 3,582 HAV isolates in the VP1/P2B region (315-bp fragment). Phylogenetic analysis of 3,582 HAV isolates in the VP1/P2B region.
SoGAT meeting XXI May (2009), Brussels, Belgium
HIS-24 and HPL associate with promoters of antimicrobial genes.
Phase 3 Treatment-Naïve and Treatment-Experienced
Sally Baylis, Piotr Grabarczyk & Jacqueline Fryer
Volume 116, Issue 3, Pages (March 1999)
Volume 22, Issue 2, Pages (February 2014)
Targeted disruption of the mouse Atp1a2.
PELP1 regulates the expression and activities of MMPs in ER-negative cells. PELP1 regulates the expression and activities of MMPs in ER-negative cells.
ANALYTICAL CONTROL SYSTEM AS A MEASURE TO ENSURE INFECTIOUS SAFETY OF HUMAN PLASMA FOR FRACTIONATION A.L. Poptsov FSBI “ROSPLASMA” RMSPC of FMBA of RUSSIA.
Presentation transcript:

GRIFOLS PLASMA: genotype 2 vB19 sample Marta José, Instituto Grifols S.A., Barcelona, SPAIN SoGAT Standardisation of Parvovirus B19 Genotypes, March 2007

Characterisation of a genotype 2 vB19 plasma sample: SAMPLE IDENTIFICATION During the validation of our current vB19 PCR method, this plasma sample was analysed by two different PCR method with the following results: An In house method, that we know that only detects the genotype 1 of vB19: NEGATIVE Our in house method, that it was designed to identify the 3 vB19 genotypes: POSITIVE Due to the discrepant results, we decide: Quantify the sample Genotype the sample SoGAT Standardisation of Parvovirus B19 Genotypes, March 2007

Characterisation of a genotype 2 vB19 plasma sample: METHODS PCR method The sample was analysed using an in-house quantitative PCR method using primers located in the VP1 capsid structural protein region. The PCR method is validated according to current guidelines for the following parameters: linearity, range, accuracy, precision, detection limit, quantitation limit, specificity and robustness. The quantitation limit was established in 2.97 log10 IU/ml. The method detects genotypes 1, 2 and 3 with the same efficacy. Genotyping Genotyping was carried out by a phylogenetic analysis as described by Candiotti et al (J. Virol 204, 76(22): 12469-12176). To do this, a 1550 bp fragment of B19 genome (NS1-VP1 region) was sequenced. SoGAT Standardisation of Parvovirus B19 Genotypes, March 2007

Characterisation of a genotype 2 vB19 plasma sample: RESULTS The plasma sample is positive for vB19 DNA and negative for HCV RNA, HIV-1 RNA, HAV RNA, HBV DNA. It is also negative for antibodies anti-HCV and anti-HIV 1/2 and for HBsAg. The titre was established in 1.90x107 IU/mL (7.3 log10 IU/mL) of vB19 DNA. The sample is negative for antibodies anti-vB19 IgG and anti-vB19 IgM using commercial ELISAs (Biotrin). Phylogenetic tree AB030694 M24682 AF162273 NC 000883 Z70528 M13178 Z70560 AF113323 AY386330 Isolate 90332 Sanquin Isolate 163429 Sanquin AY064476 AY064475 Isolate 207458 Sanquin Sample 420028819 Grifols ref sample NIBSC AY044266 AY083234 HER249437 NC 004295 AX003421 100 77 50 69 80 98 56 70 51 32 63 53 37 0,01 B19 gt 1 B19 gt 2 B19 gt 3 By sequencing a 1550 bp fragment of B19 genome (NS1-VP1 region) the sample was identified like genotype 2 according to the following phylogenetic tree. SoGAT Standardisation of Parvovirus B19 Genotypes, March 2007